1. Scrip
  2. >>Business

Can Zydus Cadila's Cut-Price Enzalutamide Shake Up Indian Market?

Nearly 90% Discount To Astellas/Pfizer’s Xtandi

 
• By Vibha Ravi

Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.

Cost effective check approval sign concept illustration design graphic
Cadila's Generic Enzalutamide Shakes Up Current Pricing • Source: Shutterstock

Zydus Cadila group's flagship firm Cadila Healthcare Ltd. has launched a generic version of Astellas Pharma Inc./Pfizer Inc.’s androgen receptor inhibitor Xtandi (enzalutamide) to treat prostate cancer at a sharp discount of 70-90% to existing brands on the Indian market.

The move underscores the potential of Indian companies to markedly disrupt pricing. This, at a time (though not a strictly comparable scenario) when Gilead Sciences Inc. finds itself at the center of a debate over pricing and access to its potential COVID-19 treatment remdesivir that was granted emergency approval by the US Food and Drugs Administration. Several Indian firms are said to be in the fray for potential voluntary licensing of remdesivir

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.